Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between t
Tweet Content
Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between those with pre-existing autoimmune disease (AID) and those without.
Mortality rates:
AID: 39.8%
Non-AID: 40.2%
Large-scale evidence supports ICIs in AID… https://t.co/BI5jK9jsoM
Show on Archive Page
On
Display in Search Results
On
PDQ
Off